BBIO - BridgeBio targets 30%+ market share for Attruby while advancing late-stage pipeline and reporting $120.7M Q3 revenue
2025-10-29 22:57:08 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call Transcript
- BridgeBio Pharma, Inc. 2025 Q3 - Results - Earnings Call Presentation
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase III Results for Encaleret in ADH1 CALIBRATE Study Transcript
- BridgeBio succeeds in late-stage encaleret study
- BridgeBio Pharma Q3 2025 Earnings Preview